The IL-33/CD4 T cell/CXCL1 System in Acute Kidney Injury

IL-33/CD4 T 细胞/CXCL1 系统在急性肾损伤中的作用

• 批准号: 8440535
• 负责人: CHARLES Louis EDELSTEIN
• 金额: --
• 依托单位: VA EASTERN COLORADO HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8440535
• 关键词: Acute Renal Failure with Renal Papillary Necrosis; Adoptive Transfer; Adverse effects; Anti-Inflammatory Agents; Antibodies; Antineoplastic Agents; Applications Grants; Attenuated; Binding; Blood Vessels; CD4 Positive T Lymphocytes; CXCL1 gene; Cancer Model; Cancer Patient; Cardiovascular Diseases; Cause of Death; Cell Death; Cells; Chemotactic Factors; Chronic Kidney Failure; Cisplatin; Clinical; Clinical Research; Complication; Data; Dendritic Cells; Development; Diabetes Mellitus; Dose; Dose-Limiting; Endothelial Cells; FDA approved; Family; Family member; Functional disorder; Future; Genetic Techniques; Grant; IL8RB gene; ITGAX gene; In Situ Hybridization; In Vitro; Infiltration; Inflammation; Inflammatory; Injection of therapeutic agent; Injury; Interleukin-1; Interleukin-18; Interleukin-8B Receptor; Kidney; Kidney Failure; Knock-out; Malignant Neoplasms; Malignant neoplasm of lung; Mediator of activation protein; Methods; Mus; Pathogenesis; Platinum; Play; Population; Production; Proteins; Protocols documentation; Publishing; Recombinants; Risk Factors; Role; Signal Transduction; Smooth Muscle Myocytes; Solid Neoplasm; Source; Staining method; Stains; System; T-Cell Depletion; Techniques; Testing; Therapeutic; Therapeutic Agents; Time; Transgenic Organisms; Tubular formation; Veterans; Withdrawal; chemokine; chemotherapeutic agent; cytokine; drug withdrawal; improved; inhibitor/antagonist; interest; macrophage; nephrotoxicity; neutrophil; novel; novel therapeutics; prevent; public health relevance; receptor; research study; tumor growth

DESCRIPTION (provided by applicant): Cisplatin and other platinum derivatives are important chemotherapeutic agents used to treat solid tumors. A known complication of cisplatin administration is acute kidney injury (AKI) which often necessitates dose reduction or withdrawal. Therefore, an understanding of the pathogenesis of cisplatin-induced AKI is important for the development of adjunctive therapies to prevent AKI and to lessen the need for dose decrease or drug withdrawal. IL-33 is a newly described pro-inflammatory cytokine in the IL-1 family that signals via the ST2 receptor. Our published data demonstrate that IL-33 inhibition attenuates CD4 T cell infiltration, renal failure and ATN, that administration of recombinant IL-33 worsens cisplatin-induced AKI and increases the chemokine CXCL1 in wild type but not CD4 -/- mice and that CD4 T cell-depletion is protective. The overall hypothesis presented in this grant provides an integrated pathophysiological schema whereby IL-33 results in CD4 T cell recruitment in the kidney, release of CXCL1 from CD4 T cells and cisplatin-induced AKI. Complementary studies will be performed in mice with cisplatin-induced AKI, mouse cancer models, endothelial cells and freshly isolated proximal tubules. Specific Aim 1 focuses on the cellular source of IL-33 and ST2 in the kidney. In Specific Aim 2, we shall determine the injurious role of IL-33 in cisplatin-induced AKI. Complimentary novel pharmacological and genetic techniques of IL-33 or ST2 inhibition will be used. The effect of IL-33, ST2 and CXCL1 inhibition and CD4 T cell knockout on cisplatin-induced AKI and the chemotherapeutic efficacy of cisplatin in mouse cancer models will be studied. Specific Aim 3 focuses on the IL-33-dependent production of CXCL1 by CD4 T cells in the kidney. The effect of CXCL1 inhibitors on AKI will be determined. CXCL1 can directly cause cell death in vitro. The effect of CXCL1 to directly cause proximal tubule injury in vitro in the absence of inflammation, will be determined. Novel experiments investigating the effect on protection against cisplatin-induced AKI by CD4 T cell depletion followed by adoptive transfer of CD4 T cells with or without the molecule of interest e.g. IL-33 will be performed. The relevance of these studies to clinical cisplatin-induced AKI is substantial and the discovery of novel mediators of cisplatin-induced AKI should provide clues to future therapies. This is particularly true because of the current availability of anti-inflammatory agents that are FDA- approved, IL-33/ST2 inhibitors that are entering clinical studies and CXCL1 inhibitors that are in clinical studies.

描述（由申请人提供）：